Skripsi
PERBANDINGAN KADAR INSULIN ANTIBODY (IA) PADA PASIEN DIABETES MELITUS TIPE 2 YANG MENDAPATKAN INSULIN GLARGIN ANALOG ORIGINATOR DENGAN INSULIN GLARGIN BIOSIMILAR DI RUMAH SAKIT MOHAMMAD HOESIN PALEMBANG
Background: The use of biosimilar insulin glargine offers a more economical therapeutic alternative compared to the originator product in the management of Type 2 Diabetes Mellitus (T2DM). However, differences in manufacturing processes for biological products have the potential to trigger different immune responses, one of which is the formation of Insulin Antibodies (IA). This study aims to compare IA levels between patients using insulin glargine analogue originator and insulin glargine biosimilar to evaluate their immunogenicity safety profile. Methods: This study was an analytic observational study with a cross-sectional design conducted at Dr. Mohammad Hoesin Hospital Palembang from October to December 2025. The study subjects consisted of 72 T2DM patients who met the inclusion criteria, divided into two groups: 36 patients using insulin glargine analogue originator and 36 patients using insulin glargine biosimilar. IA levels were measured using the ELISA (Enzyme-Linked Immunosorbent Assay) method. Statistical analysis was performed using the Mann-Whitney test to compare IA levels between the two groups. Results: Demographic characteristics and laboratory parameters (renal function, liver function, and lipid profile) were relatively equivalent between the two groups, although there was a significant difference in the duration of insulin use, which was longer in the originator group. Measurement results showed a median IA level in the originator group of 0.1667 ng/mL (range 0.0671–0.3945 ng/mL), while in the biosimilar group, it was 0.1670 ng/mL (range 0.0473–0.5214 ng/mL). Statistical tests showed no significant difference in IA levels between the two groups (p=0.710). Conclusion: There was no significant difference in Insulin Antibody (IA) levels between T2DM patients receiving insulin glargine analogue originator therapy and those receiving biosimilar. This indicates that insulin glargine biosimilar has an immunogenicity profile comparable to the originator product, making it safe for use as a therapeutic alternative. Keywords: Type 2 Diabetes Mellitus, Insulin Glargine, Biosimilar, Originator, Insulin Antibody (IA)